PainReform Ltd. (PRFX)

Market Cap	5.53M
Revenue (ttm)	n/a
Net Income (ttm)	-9.76M
Shares Out	1.56M
EPS (ttm)	-9.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,103
Open	3.78
Previous Close	3.82
Day's Range	3.55 - 3.78
52-Week Range	0.34 - 26.41
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2023

About PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 20...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 1, 2020
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: PRFX